https://www.biospace.com/press-releases/oryzon-to-host-virtual-kol-event-on-july-9-2025
ORYZON to Host Virtual KOL Event on July 9, 2025 - BioSpace
to hostjuly 9oryzonvirtualkol
https://www.benzinga.com/quote/ORYZF/earnings
ORYZON GENOMICS SA by Oryzon Genomics SA Earnings Estimates, EPS & Revenue | OTC:ORYZF | Benzinga
Discover ORYZON GENOMICS SA by Oryzon Genomics SA stock earnings estimates, EPS, and revenue analysis with Benzinga. Stay informed on ORYZF's financial...
earnings estimatesoryzongenomicssa
https://startupxplore.com/en/startups/oryzon
Oryzon profile at Startupxplore
Clinical Stage Biopharmaceutical company
oryzonprofile
https://menafn.com/1109431943/ORYZON-Announces-First-Patient-Dosed-In-NCI-Sponsored-Phase-III-Clinical-Trial-Of-Iadademstat-Plus-Immune-Checkpoint-Inhibitors-In-1L-Extensive-Stage-Small-Cell-Lung-Cancer
ORYZON Announces First Patient Dosed In NCI-Sponsored Phase I/II Clinical Trial Of Iadademstat Plus...
ORYZON Announces First Patient Dosed In NCI-Sponsored Phase I/II Clinical Trial Of Iadademstat Plus Immune Checkpoint Inhibitors In 1L Extensive Stage Small...
https://www.biospace.com/oryzon-announces-topline-results-from-phase-iib-portico-study-of-vafidemstat-in-borderline-personality-disorder-bpd
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline...
Jan 6, 2024 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a...
https://www.biospace.com/press-releases/oryzon-announces-first-patient-dosed-in-an-investigator-initiated-phase-ib-study-of-iadademstat-in-first-line-acute-myeloid-leukemia
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in...
https://www.benzinga.com/quote/ORYZF/news
Latest ORYZON GENOMICS SA by Oryzon Genomics SA Stock News | OTC:ORYZF | Benzinga
Get the latest news on ORYZON GENOMICS SA by Oryzon Genomics SA stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on...
by stocklatestoryzongenomicssa
https://www.biospace.com/oryzon-awarded-with-a-grant-for-ory-4001-from-the-als-association-in-the-u-s
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S. - BioSpace
Dec 4, 2023 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a...
https://www.home.saxo/cs-cz/markets/stocks/ory-xmce
Oryzon Genomics SA akcie | Saxo Bank
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics.
oryzongenomicssaakciebank
https://simplywall.st/stocks/es/pharmaceuticals-biotech/bme-ory/oryzon-genomics-shares/news/insufficient-growth-at-oryzon-genomics-sa-bmeory-hampers-sha
Insufficient Growth At Oryzon Genomics S.A. (BME:ORY) Hampers Share Price - Simply Wall St News
You may think that with a price-to-sales (or "P/S") ratio of 6.8x Oryzon Genomics S.A. ( BME:ORY ) is a stock worth...
https://www.biospace.com/oryzon-announces-journal-publication-of-final-phase-iia-alice-results-with-iadademstat-in-the-lancet-hematology
ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The...
Jul 17, 2024 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today that the final results of the Phase IIa ALICE study evaluating iadademstat in combination...